

**VOLUNTARY DELISTING FROM ASX UPDATE– ITL HEALTH GROUP LIMITED
(ASX:ITD)**

On 23 November 2018 ITL Health Group Limited (“ITL”) announced that it had formally applied to the ASX, following the receipt of affirmative in-principle advice subject to ITL complying with certain conditions, to voluntarily delist for the official list of the ASX.

Following this announcement ITL has now received advice that the ASX has resolved to remove ITL from the official list pending compliance with the aforementioned conditions and at a date to be agreed but likely to be before mid-February 2019.

Bill Mobbs

Executive Chairman

About ITL Health Group www.itlhealthgroup.com

ITL is an innovative global medical technology company comprising two divisions; ITL BioMedical and MyHealthTest. ITL holds an IP portfolio of more than 50 patents and sells into 55 countries.

ITL BioMedical creates and manufactures leading edge medical devices for the global blood industry including products for the clinical, blood banking, and laboratory markets. ITL is a growing provider of specialist ancillary products for the Blood Culture Testing and Blood Stream Infection Prevention markets.

MyHealthTest is developing a disruptive business model in the pathology testing market and is building an innovative platform for driving and leveraging the direct to consumer healthcare revolution.

ITL Health Group

ITL is an innovative global medical technology company comprising two divisions; ITL BioMedical and MyHealthTest. ITL holds an IP portfolio of more than 50 patents and sells into 55 countries.

ITL BioMedical creates and manufactures leading edge medical devices for the global blood industry including products for the clinical, blood banking, and laboratory markets. ITL is a growing provider of specialist ancillary products for the Blood Culture Testing and Blood Stream Infection Prevention markets.

MyHealthTest is developing a disruptive business model in the pathology testing market and is building an innovative platform for driving and leveraging the direct to consumer healthcare revolution.



Ranked 16th most Innovative Company by the
AFR Innovative Companies Awards

Australian Securities Exchange

Code: ITD

Ordinary Shares

85,552,339

Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director

Trevor Doolan	Chief Financial Officer & Company Secretary
---------------	------------------------------------------------

ITL Contact

Trevor Doolan	Company Secretary
Phone:	+61 3 9088 7991
Email:	info@itlhealthgroup.com
Address:	Level 3, 10 Moore Street, Canberra, ACT 2601

www.itlhealthgroup.com**Media**

Walbrook IR	Ben Knowles
Phone:	+61 426 277 760
Email:	ben.knowles@walbrookir.co.au